Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets.
about
Therapeutic Targets for Neurodevelopmental Disorders Emerging from Animal Models with Perinatal Immune ActivationDiverse impact of acute and long-term extracellular proteolytic activity on plasticity of neuronal excitabilityA delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disordersMatrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome.Synaptic circuit remodelling by matrix metalloproteinases in health and diseaseEphs and Ephrins in malignant gliomasTargeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesThrombospondins as key regulators of synaptogenesis in the central nervous systemMultifaceted role of matrix metalloproteinases (MMPs)Synaptically released matrix metalloproteinase activity in control of structural plasticity and the cell surface distribution of GluA1-AMPA receptorsMatrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X SyndromePotential therapeutic interventions for fragile X syndromeContributions of matrix metalloproteinases to neural plasticity, habituation, associative learning and drug addiction.Matrix metalloproteinase-7 facilitates immune access to the CNS in experimental autoimmune encephalomyelitis.Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor DrugsPlasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.The potential role of metalloproteinases in neurogenesis in the gerbil hippocampus following global forebrain ischemia.The Role of Proteases in Hippocampal Synaptic Plasticity: Putting Together Small Pieces of a Complex Puzzle.Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measuresOverexpression of matrix metalloproteinase-9 (MMP-9) rescues insulin-mediated impairment in the 5XFAD model of Alzheimer's diseaseOpen-label add-on treatment trial of minocycline in fragile X syndrome.Postnatal LPS Challenge Impacts Escape Learning and Expression of Plasticity Factors Mmp9 and Timp1 in Rats: Effects of Repeated Training.A role for matrix metalloproteinases in nicotine-induced conditioned place preference and relapse in adolescent female ratsMatrix metalloproteinases and their multiple roles in Alzheimer's disease.Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model.Decreased serum levels of mature brain-derived neurotrophic factor (BDNF), but not its precursor proBDNF, in patients with major depressive disorder.T-cell production of matrix metalloproteinases and inhibition of parasite clearance by TIMP-1 during chronic Toxoplasma infection in the brain.Astrocytes enhance the invasion potential of glioblastoma stem-like cellsHyperphagia and leptin resistance in tissue inhibitor of metalloproteinase-2 deficient mice.Doxycycline increases neurogenesis and reduces microglia in the adult hippocampusOsteopontin expression in acute immune response mediates hippocampal synaptogenesis and adaptive outcome following cortical brain injurySexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice.Matrix metalloproteinases regulate the formation of dendritic spine head protrusions during chemically induced long-term potentiation.Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?Serum matrix metalloproteinase-9 levels and severity of symptoms in boys with attention deficit hyperactivity disorder ADHD/hyperkinetic disorder HKDMatrix metalloproteinase (MMP)-9 induced by Wnt signaling increases the proliferation and migration of embryonic neural stem cells at low O2 levels.Cortical abnormalities and non-spatial learning deficits in a mouse model of CranioFrontoNasal syndrome.Plasticity associated with escalated operant ethanol self-administration during acute withdrawal in ethanol-dependent rats requires intact matrix metalloproteinase systemsNeural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinaseDecreased serum levels of brain-derived neurotrophic factor in schizophrenic patients with deficit syndrome
P2860
Q26775092-0E62B09D-264B-407C-8906-8ABA64E9E93AQ26796239-9BE134E5-838A-4ABD-A4F3-23A8214974D5Q26797397-F4409F74-D9EC-4D88-8A27-C7EEF7EB16AEQ26853083-EBA656E9-45D6-4327-A093-63AE2B79930AQ27005718-4A2368B2-AD02-4361-92D3-7EC536E1AFC7Q27015780-6B7C9839-4B4E-4FE7-8D25-F86CD14C0C99Q27023257-D0D206C5-4844-4F69-B294-920AF31D66B4Q27024828-AC93548A-B757-4655-9A4F-E0CB2F08E2CDQ28083906-4A303342-1EF9-4D7D-999E-177E5024386FQ28539061-9371343C-46C3-4D1D-88A7-1F117787EC01Q30357779-3FCBDDB0-86DE-45D0-A3ED-F45B40B2459EQ30473378-79C45801-B2FC-4587-A6C5-88F3FC8918F8Q30483239-6E8C590E-D855-4265-870A-C6DFBBCE7E69Q30486651-D7CC5686-0ECD-4489-9EC0-7A9783105A1DQ30659307-3932164F-081C-4C99-A6D2-D63576BEEE56Q30977897-66CEE762-9164-483F-9BEB-9ACCB5BDBB02Q31027921-48E2DF99-6977-4A92-BF3C-BE321414E9B2Q33361879-87DB8D2C-7D3A-4DB0-AC3C-D9D2AA6AE45FQ33650170-DE254B50-4682-46CD-B944-478B6E7A62FAQ33677609-BE9E2ACF-1961-4B7D-9EA1-A576321863C6Q33715073-A56718B3-F4D0-4A8D-8DB3-0C88332213F9Q33861298-9C7C5990-BD1B-4F75-8482-FE812A66E584Q33873222-23268545-A54F-483D-A8AD-CC6CB3294C51Q33890707-B3573E8F-BF95-49C4-B425-CC40563151BBQ33935973-8140871E-3C2C-4220-B32C-D3821DBCD4C3Q34374580-83EB2B6B-E601-4116-BE7C-F4105EEB9BC4Q34509768-F8A943A0-CE8A-43BC-95AC-74B3C263BACDQ34563444-7584B3CD-DF84-4B56-A518-224493F707C8Q34590026-069BF998-D801-4543-88EB-C8CC4C7B33DEQ34654816-8091E88A-DE1C-4B1F-942A-2D8A87A6858AQ34671588-7B79333D-793A-4757-9916-0667FB0CCA0DQ34696866-F545610A-592A-4BD2-8BD8-01C08397534CQ34733795-5DA1D063-B69F-484B-81C6-071069EB7954Q34768858-23677F57-5C23-48B6-ABE7-043198DDB356Q34924426-C7163D48-0509-4E7D-81D1-C3D15CDBAEF2Q34978937-811D025F-3DED-4BF2-808E-4300C0EAF2E3Q35092766-74E68D21-C648-4EEA-B617-B50CF576EFD3Q35141550-CEE9590C-2483-4D82-9F1C-2B3458C02625Q35232638-36307C33-F577-4E61-AE83-2A3683A943CEQ35284133-555D7A9D-16D9-4C30-9803-BE57B9378F3C
P2860
Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@ast
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@en
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@nl
type
label
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@ast
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@en
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@nl
prefLabel
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@ast
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@en
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@nl
P356
P1476
Matrix metalloproteinases in b ...... ynaptic functions and targets.
@en
P2093
Douglas W Ethell
Iryna M Ethell
P304
P356
10.1002/JNR.21273
P577
2007-10-01T00:00:00Z